Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Autor: Ole, De Backer, George D, Dangas, Hasan, Jilaihawi, Jonathon A, Leipsic, Christian J, Terkelsen, Raj, Makkar, Annapoorna S, Kini, Karsten T, Veien, Mohamed, Abdel-Wahab, Won-Keun, Kim, Prakash, Balan, Nicolas, Van Mieghem, Ole N, Mathiassen, Raban V, Jeger, Martin, Arnold, Roxana, Mehran, Ana H C, Guimarães, Bjarne L, Nørgaard, Klaus F, Kofoed, Philipp, Blanke, Stephan, Windecker, Lars, Søndergaard

Publikováno v: de Backer, O, Dangas, G D, Jilaihawi, H, Leipsic, J A, Terkelsen, C J, Makkar, R, Kini, A S, Veien, K T, Abdel-Wahab, M, Kim, W K, Balan, P, van Mieghem, N, Mathiassen, O N, Jeger, R V, Arnold, M, Mehran, R, Guimarães, A H C, Nørgaard, B L, Kofoed, K F, Blanke, P, Windecker, S, Søndergaard, L & GALILEO-4D Investigators 2020, ' Reduced leaflet motion after transcatheter aortic-valve replacement ', New England Journal of Medicine, vol. 382, no. 2, pp. 130-139 . https://doi.org/10.1056/NEJMoa1911426
De Backer, Ole; Dangas, George D; Jilaihawi, Hasan; Leipsic, Jonathon A; Terkelsen, Christian J; Makkar, Raj; Kini, Annapoorna S; Veien, Karsten T; Abdel-Wahab, Mohamed; Kim, Won-Keun; Balan, Prakash; Van Mieghem, Nicolas; Mathiassen, Ole N; Jeger, Raban V; Arnold, Martin; Mehran, Roxana; Guimarães, Ana H C; Nørgaard, Bjarne L; Kofoed, Klaus F; Blanke, Philipp; ... (2020). Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. The New England journal of medicine, 382(2), pp. 130-139. Massachusetts Medical Society 10.1056/NEJMoa1911426
De Backer, O, Dangas, G D, Jilaihawi, H, Leipsic, J A, Terkelsen, C J, Makkar, R, Kini, A S, Veien, K T, Abdel-Wahab, M, Kim, W-K, Balan, P, Van Mieghem, N, Mathiassen, O N, Jeger, R V, Arnold, M, Mehran, R, Guimarães, A H C, Nørgaard, B L, Kofoed, K F, Blanke, P, Windecker, S, Søndergaard, L & GALILEO-4D Investigators 2020, ' Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement ', The New England Journal of Medicine, vol. 382, no. 2, pp. 130-139 . https://doi.org/10.1056/NEJMoa1911426
New England Journal of Medicine, 382(2), 130-139. Massachussetts Medical Society

BACKGROUND: Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ebeb05704bbcada0c81b393bf141c9a
https://doi.org/10.1056/nejmoa1911426

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

Autor: E.L.E. de Bruijne, Marieke Emonts, Jan A. Hazelzet, M.P.M. de Maat, Frank W.G. Leebeek, Paul Declerck, Ann Gils, A H C Guimarães, Dingeman C. Rijken

Publikováno v: Journal of Thrombosis and Haemostasis. 6:268-276

Summary. Background and objectives: In pediatric meningococcal sepsis, an imbalance between coagulation and fibrinolysis and proinflammatory action play major roles. We hypothesized that thrombin activatable fibrinolysis inhibitor (TAFI) and/or TAFI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a1a3a04f11d3783ff25e8e81019e89
https://doi.org/10.1111/j.1538-7836.2007.02841.x

High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke

Autor: Diederik W.J. Dippel, Dingeman C. Rijken, M. P. M. Maat, Mary-Lou P. J. van Goor, Frank W.G. Leebeek, Ana H. C. Guimarães, G. J. Brouwers

Publikováno v: Journal of Thrombosis and Haemostasis, 3(10), 2211-2218. Wiley-Blackwell Publishing Ltd

Summary. Background and objective: Several studies have suggested that thrombin-activatable fibrinolysis inhibitor (TAFI) levels are associated with the risk of arterial thrombosis, but results have been contradictory. We studied functional TAFI leve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca475b1d51910751bf1a973c5eb3983
https://doi.org/10.1111/j.1538-7836.2005.01484.x

Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests

Autor: F. W. G. Leebeek, Dingeman C. Rijken, Simone Talens, E. L. Kock, S. Darwish Murad, Ana H. C. Guimarães, Harry L.A. Janssen

Publikováno v: Journal of Thrombosis and Haemostasis, 10(10), 2116-2122. Wiley-Blackwell Publishing Ltd

Rijken DC, Kock EL, Guimaraes AHC, Talens S, Murad S Darwish, Janssen HLA, Leebeek FWG. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 211622. Summary.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11c501003c0a4ac2aa6e596dcf5a6d8d
https://pure.eur.nl/en/publications/daedcbf6-9588-41c7-8c26-b4741ea8d367

A new functional assay of thrombin activatable fibrinolysis inhibitor

Autor: Dingeman C. Rijken, Rogier M. Bertina, Ana H. C. Guimarães

Publikováno v: Journal of Thrombosis and Haemostasis, 3(6), 1284-1292. Wiley-Blackwell Publishing Ltd

Summary. New thrombin activatable fibrinolysis inhibitor (TAFI) assays are necessary for studying the role of this fibrinolysis inhibitor in cardiovascular disease. The identification of a functional single nucleotide polymorphism (SNP) (1040C/T) lea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::526e2444c47959e3a4bb47dadc6193d1
https://pubmed.ncbi.nlm.nih.gov/15946219